Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ex VIvo DEtermiNed Cancer Therapy
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Summary
EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.
Official title: Ex Vivo Multi Drug Screening of Solid Tumours to Determine Personalised Therapy Efficacy and Resistance
Key Details
Gender
All
Age Range
16 Years - Any
Study Type
OBSERVATIONAL
Enrollment
600
Start Date
2021-07-07
Completion Date
2027-01
Last Updated
2025-02-24
Healthy Volunteers
No
Interventions
Functional drug screen
High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
Locations (1)
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorkshire, United Kingdom